2020
Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis.
Haque LY, Jakab S, Deng Y, Ciarleglio MM, Tetrault JM. Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis. Journal Of Addiction Medicine 2020, 14: e337-e343. PMID: 32530887, PMCID: PMC9033633, DOI: 10.1097/adm.0000000000000677.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersAddiction treatmentAlcohol-related liver diseaseImpact of SUDHepatitis C infectionMedical record reviewMinority of patientsNumber of hospitalizationsRoutine clinical careAlcohol use disorderHepatology clinicC infectionCause mortalityConsecutive patientsMedian ageCommon etiologyLiver diseaseRecord reviewSignificant morbidityRetrospective studySUD careCirrhosisClinical careHospitalization
2019
Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers
Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham CO, Ogbuagu O, Patel VV, Phillips KA, Tetrault JM, Shah M, Blackstock O. Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers. Preventive Medicine Reports 2019, 17: 101012. PMID: 31890474, PMCID: PMC6926349, DOI: 10.1016/j.pmedr.2019.101012.Peer-Reviewed Original ResearchPrimary care physiciansPre-exposure prophylaxisPrEP implementationPrEP prescribingPrimary careHIV pre-exposure prophylaxisMost primary care physiciansSite specialistPrimary care providersDirect patient careGuidelines/protocolsPrEP deliveryCare physiciansHIV preventionGeneral internistsCare providersClinical carePatient careCarePrEPProphylaxisNational professional organizationsImplementation barriersFuture studiesParticipants
2017
Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal Of Substance Use And Addiction Treatment 2017, 75: 49-53. PMID: 28237054, DOI: 10.1016/j.jsat.2016.12.014.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOpioid treatment programsPercent of patientsHCV treatmentHCV infectionActing antiviralsTreatment outcomesTreatment programOral HCV treatmentSustained virologic responseHCV treatment outcomesRoutine clinical careOngoing drug useVirologic responseRetrospective studyClinical careGeneral populationPatientsDrug useTreatmentOutcomesAntiviralsInfectionPercentPWID
2014
The Impact of Recent Cocaine Use on Plasma Levels of Methadone and Buprenorphine in Patients with and Without HIV-infection
Tetrault JM, McCance-Katz EF, Moody DE, Fiellin DA, Lruie BS, DInh AT, Fiellin LE. The Impact of Recent Cocaine Use on Plasma Levels of Methadone and Buprenorphine in Patients with and Without HIV-infection. Journal Of Substance Use And Addiction Treatment 2014, 51: 70-74. PMID: 25480096, DOI: 10.1016/j.jsat.2014.10.010.Peer-Reviewed Original ResearchConceptsRecent cocaine useHIV infectionCocaine useNorbuprenorphine concentrationsHIV statusBuprenorphine concentrationsS-methadoneAntiretroviral medication useBuprenorphine plasma concentrationsUninfected subjectsMethadone concentrationsMedication usePlasma levelsPlasma concentrationsR-methadoneCocaine effectsClinical careMethadoneBuprenorphineHIVInfectionAbstinenceSubjectsCocaineStatus
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence